Docosahexaenoic acid-acylated curcumin diester alleviates cisplatin-induced acute kidney injury by regulating the effect of gut microbiota on the lipopolysaccharide- and trimethylamine-<i>N</i>-oxide-mediated PI3K/Akt/NF-κB signaling pathway in mice

Shi, Hao‐Hao; Chen, Lipin; Zhao, Yang; Wang, Yuming; Xue, Changhu; Zhang, Tiantian

doi:10.1039/d1fo04178a

Cited by 20 publications

(10 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar mouse model of AKI also showed dysregulation of the gut microbiota and microbiota-derived Dserine, and D-serine supplementation attenuated tubular injury after ischemiareperfusion 18 . Furthermore, modulating gut microbiota accelerated recovery from severe ischemia-reperfusion and cisplatin-induced AKI in mice 19,20 . Mechanistically, AKI disrupts innate and adaptive immunity and metabolism and damages the intestinal epithelial barrier, resulting in "leaky gut" and dysbiosis 21 .…”

Section: Accepted Manuscriptmentioning

confidence: 99%

“…18 Furthermore, modulating gut microbiota accelerated recovery from severe ischemia-reperfusion and cisplatin-induced AKI in mice. 9,19 Mechanistically, AKI disrupts innate and adaptive immunity and metabolism and damages the intestinal epithelial barrier, resulting in "leaky gut" and dysbiosis. 20 Gut microbiotaderived uremic toxins such as trimethylamine-N-oxide (TMAO), indole sulfate, and p-cresol sulfate may exacerbate AKI, whereas other metabolites such as SCFAs and D-amino acids may alleviate AKI.…”

Section: Gut-kidney Axismentioning

confidence: 99%

See 1 more Smart Citation

Gut Microbiota and Neonatal Acute Kidney Injury

Yang,

He,

Dong

2024

Am J Perinatol

View full text Add to dashboard Cite

Neonatal acute kidney injury has a complex pathogenesis and the gut microbiota is receiving increasing attention. Gut-kidney axis establishes a bidirectional link between gut microbiota and acute kidney injury. Promoting the study of gut microbiota and neonatal acute kidney injury will contribute to early detection and treatment of this disease. A series of promising biomarkers have emerged in recent years to predict neonatal acute kidney injury earlier than serum creatinine and urine output. However, comprehensive reports on these biomarkers are relatively scarce. In addition, the gut microbiota and biomarkers associated with neonatal acute kidney injury deserve further exploration. Herein, this review summarizes the relationship between gut microbiota and neonatal acute kidney injury biomarkers to deepen our understanding of the role of the gut-kidney axis in neonatal acute kidney injury and provide potential treatment options for neonatal acute kidney injury.

show abstract

Section: Accepted Manuscriptmentioning

confidence: 99%

Section: Gut-kidney Axismentioning

confidence: 99%

Gut Microbiota and Neonatal Acute Kidney Injury

Yang,

He,

Dong

2024

Am J Perinatol

View full text Add to dashboard Cite

show abstract

“…In the other CKD models, the decreased F/B ratio was also observed in adenine-induced CKD rats, and the combination of Rehmanniae Radix Preparata (RR) and Corni Fructus (CF) significantly altered the ratio trend (Zhang et al, 2021c & 2021d). After supplementation with dietary docosahexaenoic acid-acylated curcumin diester and curcumin, the ratio of F/B was remarkably elevated in acute kidney injury mice ( Shi et al, 2022 ). Sporisorium reilianum polysaccharides could notably increase the ratio of F/B in hyperuricemic mice ( Wang et al, 2022 ).…”

Section: Animal Studies Of Natural Products For the Treatment Of Ckd ...mentioning

confidence: 99%

“…The Lachnospiraceae family, which was reduced in the CKD models, was increased by emodin nanoparticle treatment ( Lu Z. et al, 2021 ) and yam polysaccharide ( Zhang W. et al, 2021 ). The acetic acid-producing genera Lachnospiraceae UCG-001 and the Lachnospiraceae NK4A136 group, which significantly decreased in CKD rats, were drastically enriched following the intervention of RR and CF ( Zhang et al, 2021c and 2021d) and dietary docosahexaenoic acid-acylated curcumin diester or curcumin ( Shi et al, 2022 ). The genus Lactonifactor was significantly increased in the total flavones of Abelmoschus manihot treatment of the potassium oxonate-induced CRF rat model ( Tu et al, 2020 ).…”

Section: Animal Studies Of Natural Products For the Treatment Of Ckd ...mentioning

confidence: 99%

“…The small molecule compound piceatannol (PIC) could inhibit the synthesis of uremic toxin precursors in Bacillus , thereby reducing the accumulation of IS and PCS in CKD mice ( Li et al, 2022 ). The DHA-acylated curcumin diester treatment remarkably lowered the LPS and TMAO/TMA of AKI mice by decreasing the relative abundance of intestinal microflora with their metabolism ( Shi et al, 2022 ). Emodin, an abundant anthraquinone in the roots and bark of the traditional Chinese medicine rhubarb (Da Huang), has been demonstrated to reduce uremic toxins and is used in China for the treatment of CKD ( Li et al, 2015 ; Sun et al, 2019 ).…”

Section: Animal Studies Of Natural Products For the Treatment Of Ckd ...mentioning

confidence: 99%

See 1 more Smart Citation

Natural products from plants and microorganisms: Novel therapeutics for chronic kidney disease via gut microbiota regulation

et al. 2023

View full text Add to dashboard Cite

Dysbiosis of gut microbiota plays a fundamental role in the pathogenesis and development of chronic kidney disease (CKD) and its complications. Natural products from plants and microorganisms can achieve recognizable improvement in renal function and serve as an alternative treatment for chronic kidney disease patients with a long history, yet less is known on its beneficial effects on kidney injury by targeting the intestinal microbiota. In this review, we summarize studies on the effects of natural products from plants and microorganisms, including herbal medicines and their bioactive extracts, polysaccharides from plants and microorganisms, and phytochemicals, on the prevention and treatment of chronic kidney disease through targeting gut microflora. We describe the strategies of these anti-CKD effects in animal experiments including remodulation of gut microbiota structure, reduction of uremic toxins, enhancement of short-chain fatty acid (SCFA) production, regulation of intestinal inflammatory signaling, and improvement in intestinal integrity. Meanwhile, the clinical trials of different natural products in chronic kidney disease clinical practice were also analyzed and discussed. These provide information to enable a better understanding of the renoprotective effects of these effective natural products from plants and microorganisms in the treatment of chronic kidney disease. Finally, we propose the steps to prove the causal role of the intestinal microflora in the treatment of chronic kidney disease by natural products from plants and microorganisms. We also assess the future perspective that natural active products from plants and microorganisms can beneficially delay the onset and progression of kidney disease by targeting the gut flora and highlight the remaining challenges in this area. With the continuous deepening of studies in recent years, it has been proved that gut microbiota is a potential target of natural active products derived from plants and microorganisms for chronic kidney disease treatment. Fully understanding the functions and mechanisms of gut microbiota in these natural active products from plants and microorganisms is conducive to their application as an alternative therapeutic in the treatment of chronic kidney disease.

show abstract

Gut Microbiota Metabolite TMA May Mediate the Effects of TMAO on Glucose and Lipid Metabolism in C57BL/6J Mice

Li,

Yu,

Zhao

et al. 2024

Molecular Nutrition Food Res

Self Cite

View full text Add to dashboard Cite

ScopeGut microbiota can convert a variety of alkaloids and TMAO into TMA, which is then transported by the blood to the liver, and converted into TMAO. In recent years, TMAO has attracted wide attention as a metabolic risk factor in cardiovascular disease, diabetes, and other diseases. However, it is still unclear about the role of gut microbial metabolite TMA in the adverse health impacts of TMAO.Methods and resultsMale C57BL/6J is treated with intraperitoneal (i.p.) or oral TMAO for 8 weeks, the area under the OGTT curve of oral group is significantly increased by about 15% compared to the control and injection groups. Serum triglyceride levels in the oral group are significantly higher by 28.2% and 24.6% than those in the control and injection groups, respectively. Meanwhile, cholesterol content in serum is significantly elevated by 27.6% and 30.7%. Similarly, proinflammatory factors gene expressions are significantly increased with oral but not i.p. TMAO intervention. Furthermore, transformation in HepG2 cells shows that TMAO could not be converted into TMA by hepatocytes.ConclusionThe adverse effects of TMAO on glucose and lipid metabolism in C57BL/6J mice may act through gut microbiota metabolite TMA.

show abstract

Docosahexaenoic acid-acylated curcumin diester alleviates cisplatin-induced acute kidney injury by regulating the effect of gut microbiota on the lipopolysaccharide- and trimethylamine-N-oxide-mediated PI3K/Akt/NF-κB signaling pathway in mice

Abstract: A growing number of studies have reported the effects of curcumin (Cur) and docosahexaenoic acid (DHA) on alleviating acute kidney injury (AKI). In our present work, we have performed a...

Cited by 20 publications

References 46 publications

Gut Microbiota and Neonatal Acute Kidney Injury

Gut Microbiota and Neonatal Acute Kidney Injury

Natural products from plants and microorganisms: Novel therapeutics for chronic kidney disease via gut microbiota regulation

Gut Microbiota Metabolite TMA May Mediate the Effects of TMAO on Glucose and Lipid Metabolism in C57BL/6J Mice

Contact Info

Product

Resources

About